These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 20664589)
1. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Gupta A; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Vickers AJ; Schröder FH; Lilja H Br J Cancer; 2010 Aug; 103(5):708-14. PubMed ID: 20664589 [TBL] [Abstract][Full Text] [Related]
2. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522 [TBL] [Abstract][Full Text] [Related]
3. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781 [TBL] [Abstract][Full Text] [Related]
4. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177 [TBL] [Abstract][Full Text] [Related]
5. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547 [TBL] [Abstract][Full Text] [Related]
6. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616 [TBL] [Abstract][Full Text] [Related]
7. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013 [TBL] [Abstract][Full Text] [Related]
8. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475 [TBL] [Abstract][Full Text] [Related]
10. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334 [TBL] [Abstract][Full Text] [Related]
11. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H BMC Med; 2008 Jul; 6():19. PubMed ID: 18611265 [TBL] [Abstract][Full Text] [Related]
12. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790 [TBL] [Abstract][Full Text] [Related]
14. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277 [TBL] [Abstract][Full Text] [Related]
15. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
16. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895 [TBL] [Abstract][Full Text] [Related]
17. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592 [TBL] [Abstract][Full Text] [Related]
18. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531 [TBL] [Abstract][Full Text] [Related]
19. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
20. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]